HOOKIPA Pharma (HOOK) Competitors $1.26 +0.04 (+2.85%) Closing price 07/3/2025 03:13 PM EasternExtended Trading$1.26 0.00 (-0.40%) As of 07/3/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOOK vs. IMMX, ANEB, CLSD, RPTX, IRD, VTGN, ANL, GNTA, SNTI, and CUEShould you be buying HOOKIPA Pharma stock or one of its competitors? The main competitors of HOOKIPA Pharma include Immix Biopharma (IMMX), Anebulo Pharmaceuticals (ANEB), Clearside Biomedical (CLSD), Repare Therapeutics (RPTX), Opus Genetics (IRD), VistaGen Therapeutics (VTGN), Adlai Nortye (ANL), Genenta Science (GNTA), Senti Biosciences (SNTI), and Cue Biopharma (CUE). These companies are all part of the "med - biomed/gene" industry. HOOKIPA Pharma vs. Its Competitors Immix Biopharma Anebulo Pharmaceuticals Clearside Biomedical Repare Therapeutics Opus Genetics VistaGen Therapeutics Adlai Nortye Genenta Science Senti Biosciences Cue Biopharma HOOKIPA Pharma (NASDAQ:HOOK) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations. Which has better valuation and earnings, HOOK or IMMX? Immix Biopharma has lower revenue, but higher earnings than HOOKIPA Pharma. Immix Biopharma is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHOOKIPA Pharma$43.95M0.35-$43.50M-$5.85-0.22Immix BiopharmaN/AN/A-$21.61M-$0.70-3.65 Do analysts prefer HOOK or IMMX? HOOKIPA Pharma currently has a consensus price target of $4.50, indicating a potential upside of 255.73%. Immix Biopharma has a consensus price target of $7.00, indicating a potential upside of 173.97%. Given HOOKIPA Pharma's higher probable upside, equities analysts clearly believe HOOKIPA Pharma is more favorable than Immix Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HOOKIPA Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is HOOK or IMMX more profitable? Immix Biopharma has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets HOOKIPA Pharma-785.66% -120.09% -77.14% Immix Biopharma N/A -130.02%-86.33% Does the media refer more to HOOK or IMMX? In the previous week, HOOKIPA Pharma's average media sentiment score of 0.00 equaled Immix Biopharma'saverage media sentiment score. Company Overall Sentiment HOOKIPA Pharma Neutral Immix Biopharma Neutral Do insiders & institutionals believe in HOOK or IMMX? 63.9% of HOOKIPA Pharma shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 3.3% of HOOKIPA Pharma shares are owned by insiders. Comparatively, 55.4% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, HOOK or IMMX? HOOKIPA Pharma has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. SummaryHOOKIPA Pharma beats Immix Biopharma on 7 of the 12 factors compared between the two stocks. Get HOOKIPA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOOK vs. The Competition Export to ExcelMetricHOOKIPA PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.99M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.227.9419.5920.21Price / Sales0.35281.76418.25119.02Price / CashN/A42.7336.8958.10Price / Book0.307.518.035.67Net Income-$43.50M-$55.14M$3.18B$249.21M7 Day Performance1.20%4.61%2.93%3.28%1 Month Performance-17.32%4.72%3.75%5.55%1 Year Performance-77.61%5.92%35.20%21.09% HOOKIPA Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOOKHOOKIPA Pharma2.9723 of 5 stars$1.27+2.8%$4.50+255.7%-78.2%$14.99M$43.95M-0.2256IMMXImmix Biopharma3.1702 of 5 stars$2.07-4.6%$7.00+238.2%+4.3%$60.49MN/A-2.969ANEBAnebulo Pharmaceuticals2.2293 of 5 stars$1.44-1.4%$5.50+281.9%-29.0%$59.98MN/A-5.544CLSDClearside Biomedical1.4246 of 5 stars$0.80+3.9%$4.75+493.8%-35.3%$59.84M$1.66M-1.9530RPTXRepare Therapeutics2.118 of 5 stars$1.39flat$4.50+223.7%-56.9%$59.62M$53.48M-0.46180News CoverageIRDOpus Genetics1.6473 of 5 stars$0.94-3.5%$7.33+678.4%N/A$58.26M$10.99M-0.4514News CoverageGap DownVTGNVistaGen Therapeutics1.3795 of 5 stars$2.00+1.5%N/A-38.8%$57.44M$490K-1.2040ANLAdlai Nortye1.8304 of 5 stars$1.47-5.2%$9.00+512.2%-57.0%$57.20M$5M0.00127GNTAGenenta Science1.8724 of 5 stars$3.05-1.6%$25.00+719.7%N/A$56.70MN/A0.007SNTISenti Biosciences2.7063 of 5 stars$2.11-2.3%$8.50+302.8%-30.3%$56.33M$2.56M-0.194CUECue Biopharma4.0914 of 5 stars$0.68-7.9%$3.00+339.7%-29.8%$55.83M$9.29M-1.0260News Coverage Related Companies and Tools Related Companies Immix Biopharma Competitors Anebulo Pharmaceuticals Competitors Clearside Biomedical Competitors Repare Therapeutics Competitors Opus Genetics Competitors VistaGen Therapeutics Competitors Adlai Nortye Competitors Genenta Science Competitors Senti Biosciences Competitors Cue Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOOK) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HOOKIPA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HOOKIPA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
